Genmab, Novartis leukemia drug Arzerra filed for European approval

[July 09, 2015]  COPENHAGEN (Reuters) - Novartis submitted an application to the European Medicines Agency (EMA) for the use of ofatumumab, branded as Arzerra, as maintenance therapy for patients with relapsed chronic lymphocytic leukemia, its co-developer Genmab said.

The application is based on interim results from a Phase III study. Arzerra is already approved in Europe for use in combination with other drugs for some therapies.
(This version of the July 7 story was corrected to clarify that Novartis submitted application, not Genmab.)

(Reporting by Annabella Pultz Nielsen; editing by Sabina Zawadzki)

[© 2015 Thomson Reuters. All rights reserved.]

Copyright 2015 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.